Search

The role of inflammation in the pathophysiology of DMO

Diabetic macular oedema (DMO) is a major cause of visual loss in diabetes, with a complex multifactorial pathogenesis. In the UK alone it is estimated that there are nearly 2.5 million diabetic patients aged over 12 years. Approximately 65,000 of...

NICE drugs: an update on what’s good to go

Treatment options recommended by the National Institute for Health and Care Excellence (NICE) must be readily available for use in the NHS of England and Wales. This article provides an overview of recent guidance from NICE and summary advice issued...

Strengthening eye care services in Botswana through the Botswana-Addenbrooke’s Abroad VISION 2020 LINK

The VISION 2020 LINK between Botswana and Addenbrooke’s Abroad has been running for 10 years. With support from the VISION 2020 LINKS Programme two-way exchange visits were undertaken leading to the formation of the first formal international partnership under Addenbrooke’s...

IN FOCUS - The achievements and lasting effects of VISION 2020

Blindness is a major public health problem globally. The first estimate of global blindness by the World Health Organization (WHO) in 1972 provided a figure of 10 to 15 million, which was considered an underestimate [1]. In 1999, an extraordinary...

A personal reflection: working at the International Centre for Eye Health from 2006–2024

I feel incredibly fortunate to have been working part-time at the International Centre for Eye Health (ICEH) [1] since 2006. Earlier in my career, the responsibilities of work and a growing family made this merely an aspiration, and apart from...

Insights from the ‘Rb-NET Challenges’ Session: Evolving approaches in global retinoblastoma management

The Retinoblastoma Network (Rb-NET) Multidisciplinary Team (MDT) platform, developed by the London School of Hygiene & Tropical Medicine (LSHTM) and Professor Ido Didi Fabian, is a web-based telemedicine initiative that regularly hosts virtual MDT meetings focused on the evaluation and...

Regulatory drug evaluations and expedited review initiatives: EU and US perspectives

The European Medicines Agency (EMA) and United States Food and Drug Administration (FDA) each conduct independent assessments of benefit-risk profile when evaluating applications to market new or modified medicines, and their respective decision-making is guided by distinct legislation, procedures and...

Fight for Sight to maximise impact by funding solutions-focused research in priority eye conditions

Fight for Sight aims to stop sight loss by funding pioneering research. Rod McNeil takes a look at the Primer Fellowship Awards programme, which provides funding for up to £60,000 for individuals to undertake vision-related research for one year. Among...

Unconscious bias (part 2)

Does unconscious bias exist, and does training help to reduce discriminatory behaviour? Clare Inkster questions her role as a trainer. I read Gwyn Williams’ Learning Curve article on this topic a few months ago with interest, and as someone who...

The Rapid Assessment of Avoidable Blindness: How ICEH maintains the cornerstone of global eye health data

In this paper we will discuss The Rapid Assessment of Avoidable Blindness (RAAB), a survey methodology that has become the single largest source of population eye health data globally. The origins of RAAB The RAAB is a rapid, population-based survey...

An interview with Rachel Morris: Clinician wellbeing and difficult conversations

In the last wellbeing supplement, I interviewed Robert Self, Vice President of the Association of Anaesthetists, and we discussed the resources that doctors can access when experiencing problems with their wellbeing. One of those that he recommended was the podcast...